Pharma: Page 11
-
Getty Images
Novartis pays $925M to reel in a startup it helped launch
The acquisition of Anthos Therapeutics could be worth up to $3.1 billion and returns to Novartis a blood thinner it licensed to the Blackstone-backed startup six years ago.
By Ben Fidler • Feb. 11, 2025 -
stock.adobe.com/Ravi
Sponsored by Quest DiagnosticsThe role of diagnostics in advancing antibody-drug conjugates
Antibody-drug conjugates (ADCs) are revolutionizing oncology, but success requires precision diagnostics.
By Thomas P. Salvin, MD, MBA, Chief Clinical Officer, Molecular Diagnostics, Quest Diagnostics • Feb. 10, 2025 -
Explore the Trendline➔
National Institute on Aging. (2017). "Beta-Amyloid Plaques and Tau in the Brain" [Image]. Retrieved from Flickr.
TrendlineAlzheimer's disease
Many companies hope to follow in the footsteps of Biogen, Eisai and Eli Lilly by developing new therapies for the debilitating disease, which affects tens of millions of people and costs healthcare systems hundreds of billions of dollars each year.
By BioPharma Dive staff -
Getty Images
Bain buys Mitsubishi pharma unit; Bausch + Lomb deal talks come up empty
The investment firm is acquiring Mitsubishi Tanabe Pharma in a deal valued at $3.3 billion. Elsewhere, Bausch + Lomb hasn’t yet found a suitor and a pair of biotechs cut staff.
By BioPharma Dive staff • Feb. 7, 2025 -
Permission granted by Bristol-Myers Squibb
Bristol Myers, bracing for key patent losses, deepens cost-cutting plan
The pharmaceutical company plans to cut $2 billion in annual expenses by the end of 2027 through “operational efficiencies across multiple areas of the business,” its CFO told analysts on a conference call.
By Delilah Alvarado • Feb. 6, 2025 -
Scott Olson via Getty Images
Eli Lilly’s earnings, shares lifted by obesity drug sales
The drugmaker’s financial forecasts topped Wall Street’s expectations, reassuring investors after it overestimated demand for its weight loss medicines in January.
By Kristin Jensen • Feb. 6, 2025 -
Permission granted by Bristol Myers Squibb
Brain drug revivalBristol Myers gives first peek at closely watched launch of schizophrenia drug
Cobenfy, the main asset acquired through Bristol Myers’ $14 billion purchase of Karuna, had $10 million in sales in the fourth quarter and around 1,000 prescriptions weekly by late January.
By Jacob Bell • Feb. 6, 2025 -
Jeenah Moon via Getty Images
Pfizer taps former Novartis exec to lead cancer drug push
The pharmaceutical giant named Jeffrey Legos the head of a division it is counting on to overcome investor pressure and grow sales in the years ahead.
By Ben Fidler • Feb. 6, 2025 -
National Institute of Allergy and Infectious Diseases. (2017). "Human Respiratory Syncytial Virus" [Micrograph]. Retrieved from Flickr.
GSK, Pfizer sales of RSV shots slow as vaccination rates ebb
Revenue for Arexvy and Abrysvo fell sharply year over year in the fourth quarter due to narrower U.S. guidelines for their use.
By Delilah Alvarado • Feb. 5, 2025 -
Getty Images
Novo outlines new late-stage study of obesity drug CagriSema
CagriSema, which underperformed expectations in its first Phase 3 test, will be studied at different doses and for longer duration in the new trial.
By Jonathan Gardner • Feb. 5, 2025 -
Getty Images
Amgen obesity drug on hold; Regeneron sets first dividend
Elsewhere, cell therapy developer Turnstone Biologics announced a second round of layoffs and plans to explore “strategic alternatives.”
By Ned Pagliarulo • Feb. 5, 2025 -
Joe Raedle via Getty Images
Merck shares tumble as company pauses Gardasil shipments to China
Executives pulled back on a 2030 sales target of $11 billion as demand for the HPV shot shrinks amid China market turmoil.
By Jonathan Gardner • Feb. 4, 2025 -
Jacob Bell/BioPharma Dive
Pfizer drug acquired in $11B buyout confirms benefit in colon cancer
The results could sway U.S. regulators to convert Braftovi’s accelerated clearance in colorectal tumors into a full approval — boosting an oncology portfolio Pfizer is looking to for revenue growth.
By Jonathan Gardner • Feb. 3, 2025 -
Getty Images
Novartis sets ‘ambitious’ target; Skyrizi, Rinvoq sales climb
Novartis issued stronger guidance than Wall Street expected. Elsewhere, Eisai and Biogen’s Alzheimer’s drug will get a closer look in Europe and Daiichi Sankyo is switching CEOs.
By BioPharma Dive staff • Jan. 31, 2025 -
Jacob Bell/BioPharma Dive
Christophe Weber, veteran Takeda CEO, to retire next year
Julie Kim, currently Takeda’s U.S. head, will replace Weber in June 2026 and become one of the few female CEOs of a top drugmaker.
By Kristin Jensen • Jan. 30, 2025 -
Anna Moneymaker / Staff via Getty Images
Trump administrationTrump administration affirms drug price talks, but will seek input to ‘improve’ program
Democrats sought answers from RFK Jr. on how the Trump administration would handle Medicare price negotiations after a short CMS statement didn’t clear things up.
By Jonathan Gardner • Updated Jan. 30, 2025 -
Mario Tama via Getty Images
FDA clears use of Ozempic to protect kidney health
The approval adds a new indication for GLP-1 drugs and gives Novo an advantage over Lilly’s rival diabetes drug Mounjaro, which hasn’t yet proven it can improve outcomes in kidney disease.
By Kristin Jensen • Jan. 29, 2025 -
Getty Images
BioAge drops obesity drug; Akero, 89bio cash in on MASH data
BioAge scrapped the drug at the center of its $198 million initial public offering last year. Elsewhere, Akero and 89bio raised $600 million combined and Allakos laid off staff.
By BioPharma Dive staff • Jan. 29, 2025 -
Courtesy of Eisai
New Alzheimer's drugsFDA clears monthly dosing of Alzheimer’s drug Leqembi
The approval is the first to come from the FDA since the Trump administration paused external communication by health agencies last week.
By Delilah Alvarado • Jan. 27, 2025 -
Getty Images
Muscle-building drug improves body composition in obesity trial, Veru says
Shares in Veru fell by nearly half following the news, despite positive results in preserving lean muscle mass.
By Jonathan Gardner • Jan. 27, 2025 -
Permission granted by Walgreens
Sponsored by WalgreensRetail pharmacies: Biopharma’s bridge to better patient experiences and outcomes
Pharmacies play a key role in improving drug development and patient care, offering insights, clinical trial support and personalized patient programs.
Jan. 27, 2025 -
Getty Images
Novo shares climb on early data for dual-acting obesity drug
An experimental drug called amycretin showed signs it could be more potent than Eli Lilly’s rival Zepbound, though analysts cautioned certain aspects of the study may have inflated its performance.
By Jonathan Gardner • Jan. 24, 2025 -
Brian Tucker / BioPharma Dive/BioPharma Dive
The biopharma industry outlook on 2025: Uncertainty and change
The Trump administration is bringing new instability to a sector already grappling with a shaky market as well as threats like competition from China.
By Ned Pagliarulo • Jan. 24, 2025 -
Getty Images
Mixed results for Keytruda; AbbVie to work with Neomorph
Merck and Eisai reported new data for a drug regimen of Keytruda and Lenvima. Elsewhere, AstraZeneca expanded in Canada and the FDA delayed a decision on Stealth’s Barth treatment.
By BioPharma Dive staff • Jan. 24, 2025 -
Rebecca Noble via Getty Images
Senate sets date to vet RFK Jr.’s nomination to lead HHS
The Senate Finance Committee will meet on Jan. 29 to discuss the confirmation of RFK Jr., whose stances on vaccines and abortion have raised questions from Democrats and Republicans alike.
By Kristin Jensen • Jan. 23, 2025 -
Mario Tama / Staff via Getty Images
J&J joins Pfizer in detailing impact of Part D redesign
The pharma expects a modest financial headwind this year from changes to Medicare prescription drug benefits under the Inflation Reduction Act.
By Ned Pagliarulo • Jan. 22, 2025
Previous
